ダウンロード数: 231
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
29_0009.pdf | 445.6 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | 辻村, 俊策 | ja |
dc.contributor.author | 加藤, 次朗 | ja |
dc.contributor.author | 上田, 公介 | ja |
dc.contributor.author | 大田黒, 和生 | ja |
dc.contributor.alternative | Tsujimura, Shunsaku | en |
dc.contributor.alternative | Kato, Jiro | en |
dc.contributor.alternative | Ueda, Kosuke | en |
dc.contributor.alternative | Ohtaguro, Kazuo | en |
dc.date.accessioned | 2010-06-03T04:28:43Z | - |
dc.date.available | 2010-06-03T04:28:43Z | - |
dc.date.issued | 1983-01 | - |
dc.identifier.issn | 0018-1994 | - |
dc.identifier.uri | http://hdl.handle.net/2433/120107 | - |
dc.description.abstract | Eighty-eight cases of urinary bladder tumor were treated in our Department from 1976 to 1978. The effect of so-called immunopotentiators (OK-432, Levamisole and PSK) was studied in 23 patients. The following results were obtained. Pretreatment intracutaneous response to PHA was significantly lower in the high stage and high grade group than in the low stage and low grade group (P less than 0.025). However, there was no correlation between the effect of immunotherapy and PHA skin reaction. Of the immunoglobulins, only IgM was significantly lower in the high grade group than in the low grade group (P less than 0.025). The one-year survival rate for the patients in the high stage group was higher receiving immunotherapy than those not treated. This suggests that immunotherapy may be useful for prolonging the survival time of patients with advanced bladder carcinoma. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | jpn | - |
dc.publisher | 泌尿器科紀要刊行会 | ja |
dc.subject | Adjuvants, Immunologic/administration & dosage/therapeutic use | en |
dc.subject | Aged | en |
dc.subject | Antibiotics, Antineoplastic/therapeutic use | en |
dc.subject | Biological Products/therapeutic use | en |
dc.subject | Carcinoma, Squamous Cell/drug therapy/immunology | en |
dc.subject | Carcinoma, Transitional Cell/drug therapy/immunology | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Levamisole/administration & dosage/therapeutic use | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Phytohemagglutinins/immunology | en |
dc.subject | Picibanil/administration & dosage/therapeutic use | en |
dc.subject | Prognosis | en |
dc.subject | Proteoglycans/administration & dosage/therapeutic use | en |
dc.subject | Skin Tests | en |
dc.subject | Urinary Bladder Neoplasms/drug therapy/immunology | en |
dc.subject.ndc | 494.9 | - |
dc.title | いわゆる細胞性免疫能賦活剤を投与した膀胱腫瘍症例の検討 | ja |
dc.title.alternative | Treatment of tumors of the urinary bladder with so-called immunopotentiators | en |
dc.type | departmental bulletin paper | - |
dc.type.niitype | Departmental Bulletin Paper | - |
dc.identifier.ncid | AN00208315 | - |
dc.identifier.jtitle | 泌尿器科紀要 | ja |
dc.identifier.volume | 29 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 9 | - |
dc.identifier.epage | 15 | - |
dc.textversion | publisher | - |
dc.sortkey | 02 | - |
dc.address | 名古屋市立大学医学部泌尿器科学教室 | ja |
dc.address.alternative | The Department of Urology, Nagoya City University Medical School | en |
dc.identifier.pmid | 6677093 | - |
dcterms.accessRights | open access | - |
dc.identifier.pissn | 0018-1994 | - |
dc.identifier.jtitle-alternative | Acta urologica Japonica | la |
dc.identifier.jtitle-alternative | Hinyokika Kiyo | en |
出現コレクション: | Vol.29 No.1 |
![](/dspace/image/articlelinker.gif)
このリポジトリに保管されているアイテムはすべて著作権により保護されています。